• 1
    Abdullah, M.F., Rao, S.P., Magno, V., Da Costa M (1998) Platelet dysfunction in children with AIDS (abstract 3068). Blood, 92 (10) (Suppl. 1).
  • 2
    Allen, G.C., Armfield, D.R., Bontempo, F.A., Kingsley, L.A., Goldstein, N.A., Post J.C (1999) Adenotonsillectomy in children with von Willebrand disease. Archives of Otolaryngology — Head and Neck Surgery, 125, 547 551.
  • 3
    Amin, D.M., Mant, T.G., Walker, S.M., Kerry, R., Lloyd, P., Lefevre, G., Close P (1997) Effect of a 15-minute infusion of DDAVP on the pharmacokinetics and pharmacodynamics of REVASC during a four-hour intravenous infusion in healthy male volunteers. Thrombosis and Haemostasis, 77, 127 132.
  • 4
    Becton, C., Cornell, C., Gill, U., Shapiro, A., Thompson A (1998) Evaluation of the efficacy and safety of Stimate (desmopressin acetate) nasal spray, 1.5 mg/mL: an expanded database (abstract 134). Blood, 92 (10) (Suppl. 1).
  • 5
    Borchiellini, A., Fijnvandraat, K., Ten Cate, J.W., Pajkert, D., Van Deventer, S.J., Pasterkamp, G., Meijer Huizinga, F., Zwart Huinink, L., Voorberg, J., Van Mourik J.A (1996) Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood, 88, 2951 2958.
  • 6
    Budde, U., Brackmann, H.H., Etzel F (1980) Einsatz von DDAVP bei zahnärztlichen Eingriffen bei Patienten mit von Willebrand-Syndrom und einem Patienten mit kombiniertem Hermansky-Pudlak-Syndrom und leichtem von Willebrand-Syndrom. In: DDAVP in Bleeding Disorders (ed. by A.H. Sutor), pp. 148 153. Schattauer, Stuttgart, New York.
  • 7
    Canciani, M.T., Federici, A.B., Stabile, F., Baronciani, L., Cozzi, G., Forza, I., Mannucci P.M (1999) New candidate mutation Arg1308LEU in a family with type 2B von Willebrand's disease characterized by all sets of multimers in plasma and no thrombocytopenia before and after desmopressin (abstract 885). Thrombosis and Haemostasis, 82, 282.
  • 8
    Casanato, A., Steffan, A., Pontara, E., Zucchetto, A., Rossi, C., De Marco, L., Girolami A (1999) Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thrombosis and Haemostasis, 81, 224 228.
  • 9
    Castaman, G., Ruggeri, M., Rodeghiero F (1996) Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency. British Journal of Haematology, 94, 168 170.
  • 10
    Cattaneo M (1997) Review of clinical experience of desmopressin in patients with congenital and acquired bleeding disorders. European Journal of Anaesthesiology, Suppl. 14, 10 14.
  • 11
    Cattaneo, M., Pareti, F.I., Zighetti, M.L., Lecchi, A., Lombardi, R., Mannucci P.M (1995a) Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time. Journal of Laboratory and Clinical Medicine, 125, 540 547.
  • 12
    Cattaneo, M., Harris, A.S., Stromberg, U., Mannucci, P. & M. (1995b) The effect of desmopressin on reducing blood loss in cardiac surgery — a meta-analysis of double-blind, placebo-controlled trials. Thrombosis and Haemostasis, 74, 1064 1070.
  • 13
    Chen, K.S., Huang, C.C., Leu, M.L., Deng, P., Lo S.K (1997) Hemostatic and fibrinolytic response to desmopressin in uremic patients. Blood Purification, 15, 84 91.
  • 14
    Conroy, J.M., Fishman, R.L., Reeves, S.T., Pinosky, M.L., Lazarchick J (1996) The effects of desmopressin and 6% hydroxyethyl starch on factor VIII:C. Anesthesia and Analgesia, 83, 804 807.
  • 15
    Cunniff, C. & Williamson Kruse L (1995) Ehlers–Danlos syndrome, type VIII presenting with periodontitis and prolonged bleeding time. Clinical Dysmorphology, 4, 145 149.
  • 16
    Cuthbert, R.J.G., Watson, H.K., Handa, S.I., Abbott, I., Ludlam C.A (1988) DDAVP shortens the bleeding time in Bernard–Soulier syndrome. Thrombosis Research, 49, 649 650.
  • 17
    Deitcher, S.R., Tuller, J., Johnson J.A (1999) Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia, 5, 88 95.
  • 18
    Derkay, C.S., Werner, E., Plotnick E (1996) Management of children with von Willebrand disease undergoing adenotonsillectomy. American Journal of Otolaryngology, 17, 172 177.
  • 19
    Despotis, G.J., Levine, V., Saleem, R., Joist, H.J., Spitznagel E (1999) DDAVP reduces blood loss and transfusion in cardiac surgical patients with impaired platelet function identified using a point-of-care test: a double blind, placebo-controlled trial (abstract 2325). Thrombosis and Haemostasis, 82, 735.
  • 20
    Di Michele, D. & Hathaway W.E (1990) Use of DDAVP in inherited and acquired platelet dysfunction. American Journal of Hematology, 33, 39 45.
  • 21
    Edlund, M. & Blombäck M (1997) Desmopressin in the treatment of menorrhagia (abstract). Thrombosis and Haemostasis, 78 (Suppl. 1), 444.
  • 22
    Epsanol, I., Hernandez, A., Pujol, R.M., Urrutia, T., Pujol-Moix N (1998) Type IV Ehlers–Danlos syndrome with platelet delta-storage pool disease. Annals of Hematology, 77, 47 50.DOI: 10.1007/s002770050410
  • 23
    Farias, C., Kempfer, A.C., Carballo, G., Blanco, A., Woods, A., Menschengiese, S., Lazzari M (1997) Laboratory monitoring of desmopressin (DDAVP) in patients with von Willebrand's disease (vWD) using collagen binding assay (CBA) (abstract). Thrombosis and Haemostasis, 78 (Suppl), 698 (PS–2846).
  • 24
    Federici, A.B. & Mannucci P.M (1998) Optimizing therapy with factor VIII von Willebrand factor concentrates in von Willebrand disease. Haemophilia, 4, 7 10.
  • 25
    Federici, A.B., Berntorp, E., Lee, C.A., Scharrer, I., Goudemand, J., Stabile, F., Lethagen, S., Nitu, I., Ludwig, G., Mannucci P.M (1999) A standard trial infusion with desmopressin is always required before Factor VIII/von Willebrand factor concentrates in severe type 1 and 2 von Willebrand disease: results of a multicenter European study (abstract 2518). Thrombosis and Haemostasis, 82, 795.
  • 26
    Flordal P.A (1998) Use of desmopressin to prevent bleeding in surgery. European Journal of Surgery, 164, 5 11.
  • 27
    Fowler, W.E., Berkowitz, L.R., Roberts H.R (1989) DDAVP for type IIB von Willebrand disease. Blood, 74, 1859 1860.
  • 28
    Franchini, M., De Gironcoli, M., Lippi, G., Manzato, F., Aprili, G., Vassanelli, A., Benini, F., Gandini G (1999) Use of subcutaneous desmopressin (DDAVP) as surgical prophylaxis in 5 symptomatic heterozygous factor XI (FXI) deficient patients (abstract 429). Thrombosis and Haemostasis, 82, 138 139.
  • 29
    Fressinaud, E., Federici, A.B., Castaman, G., Rothschild, C., Rodeghiero, F., Baumgartner, H.R., Mannucci, P.M., Meyer D (1994) The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease. British Journal of Haematology, 86, 327 332.
  • 30
    Van Genderen, P.J.J. & Michiels J.J (1998) Acquired von Willebrand disease. Baillière's Clinical Haematology, 11, 319 330.
  • 31
    Gill, J.C., Wilson, A.D., Endres-Brooks, J., Montgomery R.R (1986) Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood, 67, 758 761.
  • 32
    Goudemand, J., Caron, C., Rugeri, L., Siaka, C., Tournoys A (1999) Management of patients with von Willebrand's disease: PFA can help to predict the efficacy of treatment with DDAVP but not of treatment with VWF concentrates (abstract 2519). Thrombosis and Haemostasis, 82, 795 796.
  • 33
    Gralnick, H.R., Williams, S.B., McKeown, L.P., Rick, M.E., Maisonneuve, P., Jenneau, C., Sultan Y (1986) DDAVP in type IIa von Willebrand's disease. Blood, 67, 465 468.
  • 34
    Greinacher, A., Pötzsch, B., Kiefel, V., White, J.G., Müller-Berghaus, G., Mueller-Eckhardt, Ch.R. (1993) Evidence that DDAVP transiently improves hemostasis in Bernard–Soulier syndrome independent of von Willebrand factor. Annals of Hematology, 67, 149 150.
  • 35
    Guay, J. & Rivard G.E (1996) Medistinal bleeding after cardiopulmonary bypass in pediatric patients. Annals of Thoracic Surgery, 62, 1955 1960.
  • 36
    Hashemi, S., Palmer, D.S., Aye, M.T., Ganz P.R (1993) Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. Journal of Cell Physiology, 154, 496 505.
  • 37
    Hay, C.R. & M. (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia, 4, 558 563.
  • 38
    Herdeg, S., Peters, A., Baier, P., Zieger, B., Sutor A.H (1998) Continuous infusion of von Willebrand-Factor (vWF)-containing F-VIII-concentrate in a girl with von Willebrand's disease (vWD) 2B (abstract 117). Haemophilia, 4, 184.
  • 39
    Jürgensen, B., Merten, H.A., Wieding J.U (1998) DDAVP dose reduction to 0.2 μg/kg: Normalization of aspirin-induced bleeding tendency but reduction of adverse effects (abstract). Annals of Hematology, 76, A33.
  • 40
    Jy, W., Horstman, L.L., Park, H., Mao, W.W., Valant, P., Ahn Y.S (1998) Platelet aggregates as markers of platelet activation: characterization of flow cytometric method suitable for clinical applications. American Journal of Hematology, 57, 33 42.DOI: 10.1002/(sici)1096-8652(199801)57:1<33::aid-ajh6>;2-2
  • 41
    Kavakli, K., Polat, A., Hüseyinof, A., Nisli, G., Aydinok Y (1999) Plasma platelet activating factor (PAF) levels and desmopressin response in children with haemophilia and von Willebrand's disease. Thrombosis and Haemostasis, 81, 665 667.
  • 42
    Kehmali, S., Canatan, D., Uysal, Z., Akar, N., Cin, S., Arcasoy A (1994) DDAVP shortens bleeding time in Bernard–Soulier syndrome (letter). Thrombosis and Haemostasis, 71, 675.
  • 43
    Keularts, I.M.L.W., Beguin, S., Hamulyak, K., Hemker C (1999) Von Willebrand factor plays a key role in thrombin generation in platelet-rich plasma (abstract 1602). Thrombosis and Haemostasis, 82, 509.
  • 44
    Kim, H.C., Salva, K., Fallot, P.L., Karp, G.I., Eisele, J., Matts, L., Heller, I., Saidi P (1988) Patients with prolonged bleeding time of undefined etiology, and their response to desmopressin. Thrombosis and Hemostasis, 59, 221 224.
  • 45
    Kobrinsky, N.L. & Tulloch H (1998) Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). Journal of Pediatrics, 112, 993 995.
  • 46
    Köhler, M. & Wieding J.U (1993) Roles of desmopressin and vasopressin in haemostasis. In: Vasopressin (ed. by P. Gross, D. Richter & G.L. Robertson), pp. 441 454. John Libbey Eurotext, Paris, France.
  • 47
    Kosch, A., Kehrel, B., Nowak-Göttl, U., Häberle, J., Jürgens H (1999) Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-arginine vasopressin. Klinische Pädiatrie, 211, 198 200.
  • 48
    Kouides, P., Phatak, P., Sham, R., Braggins, C., Miller, G., Cox, C., Howard F (1998) The increased prevalence of subnormal von Willebrand factor levels and blood type O in menorrhagia (abstract 2283). Blood, 92 (10) (Suppl. 1).
  • 49
    Kreuz, W., Mentzer, D., Becker, S., Scharrer, I., Kornhuber B (1994) Haemate P in children with von Willebrand's disease. Haemostasis, 24, 304 310.
  • 50
    Ledford, M.R., Rabinowitz, I., Sadler, J.E., Kent, J.W., Civantos F (1993) New variant of von Willebrand disease type II with markedly increased levels of von Willebrand factor antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami. Blood, 82, 169 175.
  • 51
    Lethagen S (1997) Desmopressin — a haemostatic drug: state-of-the-art review European Journal of Anaesthesiology, Suppl. 14, 1 9.
  • 52
    Lethagen, S. & Nilsson I.M (1992) DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. European Journal of Haematology, 49, 7 13.
  • 53
    Letts, M., Pang, E., D'astous, J., Jarvis, J., Lawton, L., Luke, B., Rhine, E., Menard E (1998) The influence of desmopressin on blood loss during spinal fusion surgery in neuromuscular patients. Spine, 23, 475 478.
  • 54
    Lopez, J.A., Andrews, K., Afsahr-Khargan, V., Berndt, M. & C. (1998) Bernard–Soulier Syndrome. Blood, 91, 4397 4418.
  • 55
    Lozano, M., Escolar, G., Monteagudo, J., Pico, M., Ordinas A (1995) Hemostatic effect of DDAVP infusions on a Bernard–Soulier syndrome patient: studies under flow conditions (abstract). Thrombosis and Haemostasis, 73, 265 275.
  • 56
    Lusher J.M (1994) Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease. Haemostasis, 24, 276 284.
  • 57
    McKeown, L.P., Connaghan, G., Wilson, O., Hansmann, K., Merryman, P., Gralnick H.R (1996) 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease. American Journal of Hematology, 51, 158 163.DOI: 10.1002/(sici)1096-8652(199602)51:2<158::aid-ajh11>;2-e
  • 58
    McLellan, D.S., Knight, S., McLellan, H.G., Wassef, M., Aronstam A (1985) The influence of DDAVP on the survival of factor VIII in severe hemophiliacs. Thrombosis Research, 40, 113 119.
  • 59
    Manno, C.S., Bulter, R.B., Cohen A.R (1998) Successful management of patients with type 1 von Willebrand's disease with desmopressin acetate for tonsillectomy (abstract). Haemophilia, 4, 288.
  • 60
    Mannucci P.M (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood, 90, 2515 2521.
  • 61
    Mannucci, P.M. & Bianchi A (1994) Desmopressin, surgery and thrombosis. Thrombosis and Haemostasis, 71, 154 161.
  • 62
    Mannucci, P.M., Ruggeri, Z.M., Pareti, F.I., Capitanio A (1977) DDAVP: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet, 1, 869 872.
  • 63
    Mannucci, P.M., Vicente, V., Viallo, L., Cattaneo, M., Alberca, I., Coccato, M.P., Faioni, E., Mari D (1986) Controlled trial of desmopressin (DDAVP) in liver cirrhosis and other conditions associated with prolonged bleeding time. Blood, 67, 1148 1153.
  • 64
    Mant M (1988) DDAVP in Bernard–Soulier syndrome. Thrombosis Research, 52, 77 78.
  • 65
    Maritinez-Murillo, C., Quintana, G.S., Ambriz, E.R., Payns, B.E., Arias, A.A., Arzate, G., Rodriguez-Moyado, H., Gutierrez R.M (1994) Treatment of the hereditary platelet function defects as gray platelet syndrome and Bernard–Soulier syndrome with DDAVP (abstract). Blood, 84, 688a.
  • 66
    Martinez-Murillo, C., Quintana-Gonzalez, S., Ambriz-Fernandez, R., Arzate-Hernandez, G., Gutierrez-Romero, M., Gaminio-Gomez E (1997) Utility of desmopressin in 4 cases of thrombocytopathies associated with giant platelets. Revista de Investigacion Clinica, 49, 281 286.
  • 67
    Mauz-Korholz, C., Budde, U., Kruck, H., Korholz, D., Göbel U (1998) Management of severe chronic thrombocytopenia in von Willebrand's disease type 2B. Archives of Diseases in Childhood, 78, 257 260.
  • 68
    Mayer, K., Schildknecht, O., Von Felten A (1997) May-Hegglin-Anomalie: ergänzende Untersuchungen zur Frage der Thrombozyten-Funktionsstörung. Schweizer Medizinische Wochenschrift, 127, 1134 1140.
  • 69
    Mazurier, C., Gaucher, C., Jorieux, S., Goudemand M (1994) Biological effect of desmopressin in eight patients with type 2N (‘Normandy') von Willebrand disease. Collaborative Group. British Journal of Haematology, 88, 849 854.
  • 70
    Mentzer, D., Burgsmüller, G., Heller, C., Andrischke, K., Scharrer, I., Kreuz W (1997) Sufficient increase of clotting factors after reduced DDVP test-dosage in von Willebrand's disease type 1 (abstract). Thrombosis and Haemostasis, PS2839, 696.
  • 71
    Moudgil, A. & Kamil E.S (1996) Protracted, gross hematuria in sickle cell trait: response to multiple doses of 1-desamino-8-D-arginine vasopressin. Pediatric Nephrology, 10, 210 212.DOI: 10.1007/s004670050099
  • 72
    Mudad, R.K.W.H. & Kane W.H (1993) DDAVP in acquired hemophilia A: case report and review of the literature. American Journal of Hematology, 43, 295 259.
  • 73
    Musso, R., Russo, M., Cultrera, D., Sortino, G., Ventrurio, L., Ferlito, C., Salemi, S., Azzaro, M.P., Giustolisi R (1998) Usefulness of subcutaneous concentrated desmopressin for bleeding symptoms in patients with combined factor V/VIII deficiency (abstract 3442). Blood, 92 (10) (Suppl. 1).
  • 74
    Nishino, M., Nishino, S., Sugimoto, M., Shibata, M., Tsuji, S., Yoshioka A (1996) Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy. International Journal of Hematology, 64, 127 134.DOI: 10.1016/0925-5710(96)00470-7
  • 75
    Nitu, I.C., Owents, D., Jenkins, P.V., Lee, C.A., Pasi K.J (1998) Infusion trial with desmopressin (DDAVP) in patients with severe hereditary von Willebrand's disease (abstract 3443). Blood, 92 (10) (Suppl. 1).
  • 76
    Noris, P., Arbustini, E., Spedini, P., Belletti, S., Balduini C.L (1998) A new variant of Bernard–Soulier syndrome characterized by dysfunctional glycoprotein (GP) Ib and severely reduced amounts of GPIX and GPV. British Journal of Haematology, 103, 1004 1013.
  • 77
    Orth, M. & Sutor A.H (1991) Hermansky–Pudlak Syndrom. In: Diagnosestellung und Therapiemöglichkeit Mit DDAVP (ed. by G. Landbeck, I. Scharrer & W. Schramm), p. 304. Springer, Berlin.
  • 78
    Rao, A.K., Ghosh, S., Sun, L., Yang, X., Disa, J., Pickens, P., Polansky M (1995) Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. Thrombosis and Haemostasis, 74, 1071 1078.
  • 79
    Rendal, E., Torea, J.H., Penas, N., Larrabeiti, B., Vale, A., López Fernández, M.F., Batle J (1999) Type 2B von Willebrand's disease due to Val553Met missense mutation associated to different phenotypic pattern in the same sibship (abstract 2889). Thrombosis and Haemostasis, 82, 284.
  • 80
    Rey J.G (1998) DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstetrical and Gynecological Surveys, 53, 450 455.
  • 81
    Riechelmann, H., Keller, M., Ohler W (1994) Von Willebrand-Syndrom — Blutungsrisiko bei HNO-Eingriffen im Kindesalter. Laryngorhinootologie, 73, 346 348.
  • 82
    Robbins, D., Kulkarni, R., Gera, R., Emuakapor, S.A., Bosma, K., Penner J.A (1999) Long term intranasal desmopressin acetate prophylaxis and avoidance of Factor VIII concentrates (FVIIIC) in mild hemophilia A (MHA) with high titer inhibitors (HTI) (abstract). Thrombosis and Haemostasis, 82, 296.
  • 83
    Robson, W.L., Norgaard, J.P., Leung A.K (1996) Hyponatremia in patients with nocturnal enuresis treated with DDAVP. European Journal of Pediatrics, 155, 959 962.
  • 84
    Rodeghiero, F., Castaman, G., Mannucci. P.M. (1996) Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thrombosis and Haemostasis, 76, 692 696.
  • 85
    Romeuf de, C., Hilbert, L., Mazurier C (1998) Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations. Thrombosis and Haemostasis, 79, 211 216.
  • 86
    Schneppenheim, R., Thomas, K.B., Sutor A.H (1995) Von Willebrand disease in childhood. Seminars in Thrombosis and Hemostasis, 21, 261 275.
  • 87
    Schulman, S. & Johnsson H (1991) Heparin, DDAVP and the bleeding time. Thrombosis and Haemostasis, 65, 242 244.
  • 88
    Schwab, M. & Ruder H (1997) Hyponatraemia and cerebral convulsion due to DDAVP administration in patients with enuresis nocturna or urine concentration testing (letter). European Journal of Pediatrics, 156, 668.
  • 89
    Shah, S., Lalwani, A.K., Koerper M.A (1998) Perioperative management of von Willebrand's disease in otolaryngologic surgery. Laryngoscope, 108, 32 36.
  • 90
    Sheridan, D.P., Card, R.T., Pinilla, J.C., Harding, S.M., Thomson, D.J., Gauthier, L., Drotar D (1994) Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Canadian Journal of Surgery, 37, 33 336.
  • 91
    Stine, K.C. & Becton D.L (1997) DDAVP therapy controls bleeding in Ehlers–Danlos syndrome. Journal of Pediatric Hematology/Oncology, 19, 156 158.
  • 92
    Sutor A.H (ed.) (1980) DDAVP in Bleeding Disorders. Schattauer, Stuttgart, New York.
  • 93
    Sutor A.H (1981) Gegenwärtiger Stand der DDAVP-Anwendung bei Blutern. In: Vasopressin Analogues and Haemostasis DDAVP (Minirin) TGLVP (Glycylpressin) (ed. by A.H. Sutor), pp. 6 11. Schattauer, Stuttgart, New York.
  • 94
    Sutor A.H (1998a) Desmopressin (DDAVP) in bleeding disorders of childhood. Seminars in Thrombosis and Hemostasis, 24, 555 566.
  • 95
    Sutor A.H (1998b) The bleeding time in pediatrics. Seminars in Thrombosis and Haemostasis, 24, 577 582.
  • 96
    Sutor, A.H. & Schwöbel B (1996) DDAVP-Therapie bei mittelschwerer/leichter Hämophilie B. In: 26 Hämophilie-Symposion, Hamburg 1995 (ed. by I. Scharrer & W. Schramm), pp. 122 127. Springer, Berlin, Heidelberg.
  • 97
    Sutor, A.H., Pollmann, H., Arends P (1980) Intranasale Anwendung von DDAVP bei schwerer Hämophilie A und B. In: International Symposium on DDAVP in Bleeding Disorders (ed. by A.H. Sutor), pp. 109 114. Schattauer-Verlag, Stuttgart, New York.
  • 98
    Theroux, M.C., Cordry, D.H., Tietz, A.E., Miller, F., Peoples, J.D., Kettrick R.G (1997) A study of desmopressin and blood loss during spinal fusion for neuromuscular scoliosis: a randomized, controlled, double-blinded study. Anesthesiology, 87, 260 267.
  • 99
    Thomas, K.B., Sutor, A.H., Altinkaya, N., Grohmann, A., Zehenter, A., Leititis J.U (1995) von Willebrand factor collagen binding activity is increased in newborns and infants. Acta Paediatrica, 84, 697 699.
  • 100
    Thomas, K.B., Zieger, B., Grohmann, A., Vigh, T., Eckhoff-Donovan, S., Scharrer, I., Sutor A.H (1997) Evaluation of laboratory tests used to monitor 1-Deamino-8-D-arginine Vasopressin infusion: preliminary results, 1995. In: 26 Hämophilie Symposium Hamburg (ed. by I. Scharrer & W. Schramm), pp. 121 127. Springer, Berlin.
  • 101
    Uno, H., Nishida, N., Ishizaki, J., Suzuki, M., Nishikubo, T., Miyata, S., Takahashi, Y., Yoshioka, A., Tsuda K (1994) Investigation of type IIC von Willebrand disease. International Journal of Hematology, 59, 219 225.
  • 102
    Waldenström, E., Holmberg, I., Axelsson, U., Winquist, I., Nilsson I.M (1991) Bernard–Soulier syndrome in two Swedish families: effect of DDAVP on bleeding time. European Journal of Haematology, 46, 182 187.
  • 103
    Wall, U., Jern, S., Tengborn, L., Jern C (1998) Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood, 91, 529 537.
  • 104
    Wang Yingchun, Zhang Jingyu, Ruan Changgeng (1999) A novel mutation Ala1500Glu responsible for type 2A von Willebrand disease (abstract 406). Thrombosis and Haemostasis, 82, 131.
  • 105
    Wieting, J.M., Dykstra, D.D., Ruggiero, M.P., Robbins, G.B., Galusha K (1997) Central nervous system ischemia after varicella infection and desmopressin therapy for enuresis. Journal of the American Osteopathic Association, 97, 293 295.
  • 106
    Zieger, B., Budde, U., Jessat, U., Zimmermann, R., Simon, M., Kätzel, R., Sutor A.H (1998a) New families with von Willebrand's disease type 2M (Vicenza). Thrombosis Research, 87, 57 64.DOI: 10.1016/s0049-3848(97)00104-7
  • 107
    Zieger, B., Budde, U., Peters, A., Sutor A.H (1998b) Impact of diagnosis in von Willebrand's syndrome type 2A for therapy (abstract 509). Haemophilia, 4, 283.